|
Item
#14
CuraGen,
Bayer Research Alliance Agreed to Clinically Develop 12 New Drugs
The
$1.4 billion obesity and diabetes research partnership launched by
Bayer and CuraGen has begun to bear fruit, the companies said on
Wednesday.
The
two have chosen 31 small molecule targets in obesity and diabetes
and have finished screening against four of those targets. The
CuraGen targets are designated as "high priority" for
screening at Bayer, the companies said in a statement.
The
two companies struck their massive deal in early 2001. CuraGen
agreed to provide 80 drug targets for obesity and diabetes in the
course of five years. The two jointly agreed to bring 12 drugs to
clinical development, sharing both late-stage preclinical and
clinical development costs and profits for any resulting drugs.
CuraGen is supplying its pharmacogenomic, bioinformatics,
and functional genomics knowledge, and Bayer is handling
high-throughput screening, combinatorial chemistry, medicinal
chemistry, and pharmacology.
================================
FACT:
If
urine microalbumin levels are high, ACE-inhibitors should be
considered even if blood pressure is normal.
================================
Back / Next Item
[an error occurred while processing this directive]
|
